The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
- Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
- Chuikyo Approves Listing of 5 Drugs with Expected Peak Sales of Over 10 Billion Yen
May 14, 2015
- Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
- MHLW Mulls Legal Disclosure of Drug Makers’ Clinical Research Payments
May 13, 2015
- Chuikyo to Begin Open Debates on Cost-Effectiveness Case Study from Late May: Official
May 12, 2015
- Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion
May 12, 2015
- Applications for Sakigake Review System May Be Accepted from Early Stage of Development: Official
May 12, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 20 - May 10
May 11, 2015
- PMDA Evaluating Xalkori for Risk of Cardiac Failure
May 11, 2015
- Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
- 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
- DPC Hospitals with Generic Use Rates Above 60% More Than Doubled
May 1, 2015
- MHLW to Give Medical Subsidies for 196 “Designated Intractable Diseases” from July
May 1, 2015
- PAFSC 1st Committee Recommends Irribow Use in Females
May 1, 2015
- Submission of CDISC-Based Clinical Data Required from October 2016: Notification
April 30, 2015
- Thrombocytopenia Added to Clinically Significant ADR List for Januvia, Glactiv: Safety Bulletin
April 30, 2015
- Scrutinize Purpose of Price Maintenance Premium for New Drugs: MOF
April 28, 2015
- MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
- Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…